A Multiple-Dose Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of MK-1075 in GT3 and GT1 HCV Infected Patients
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2016
At a glance
- Drugs MK 1075 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 20 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 08 Sep 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 a per ClinicalTrials.gov record.